Format

Send to

Choose Destination
Autophagy. 2018;14(12):2155-2170. doi: 10.1080/15548627.2018.1501134. Epub 2018 Sep 11.

HMGB1 represses the anti-cancer activity of sunitinib by governing TP53 autophagic degradation via its nucleus-to-cytoplasm transport.

Author information

1
a Institute of Pharmacology & Toxicology, College of Pharmaceutical Sciences , Zhejiang University , Hangzhou , China.
2
b Department of Oncology , Hangzhou First People's Hospital, Nanjing Medical University , Hangzhou , China.

Abstract

Sunitinib, a multikinase inhibitor approved for a number of cancer indications has a low response rate. Identifying mechanisms of resistance could lead to rational combination regimens that could improve clinical outcomes. Here we report that resistance to sunitinib therapy was driven by autophagic degradation of TP53/p53. Deletion of ATG7 or ATG5 suppressed TP53 degradation, as did knockdown of SQSTM1/p62. Mechanistically, the transport of TP53 from the nucleus to the cytoplasm was essential for the sunitinib-induced autophagic degradation of TP53 and did not require TP53 nuclear export signals (NESs). Moreover, TP53 degradation was achieved by the transport of its nuclear binding target, HMGB1, which shifted TP53 from the nucleus to the cytoplasm. The inhibition of HMGB1 sensitized cancer cells to sunitinib. Importantly, sunitinib induced the degradation of all TP53 proteins, except for TP53 proteins with mutations in the interaction domain of TP53 with HMGB1 (amino acids 313 to 352). In conclusion, our data identify an alternative HMGB1-mediated TP53 protein turnover mechanism that participates in the resistance of sunitinib and suggest HMGB1 as a potential therapeutic target for improving clinical outcomes of sunitinib.

KEYWORDS:

Autophagy-lysosomal degradation; HMGB1; TP53; nuclear export; sunitinib

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center